Development and validation of liquid chromatography-tandem mass spectrometric method for simultaneous determination of fosinopril and its active metabolite fosinoprilat in human plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 854, Issue 1-2, 2007, Pages 143-151

  Cui, Shuangjin ^a   Feng, Fang ^a   Ma, Ming ^a   Liu, Han ^a   Chen, Yun ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b INSTITUTE OF DERMATOLOGY   (China)

Author keywords

Fosinopril; Fosinoprilat; Human plasma; Liquid chromatography tandem mass spectrometry; Pharmacokinetics

Indexed keywords

DRUG PRODUCTS; IONIZATION; LIQUID CHROMATOGRAPHY; MAMMALS; MASS SPECTROMETRY; METABOLITES;

FOSINOPRIL; FOSINOPRILAT; HUMAN PLASMA; TANDEM MASS SPECTROMETRY;

PHARMACOKINETICS;

FOSINOPRIL; FOSINOPRILAT; ZALEPLON;

ACCURACY; ADULT; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG METABOLISM; DRUG QUALITY; DRUG STABILITY; ELECTROSPRAY; FEMALE; HUMAN; IONIZATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; STANDARD; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FOSINOPRIL; HUMANS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 34250695963     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2007.04.019     Document Type: Article

References (20)

1. Deforrest J.M., Waldron T.L., and Harveyl C.M. J. Cardiovas. Pharm. 14 (1989) 730
2. Morrison R.A., Singhvi S.M., and Povetti D. Pharmacologist 29 (1987) 149
3. Duchin K.L., Manning J.A., McKinstry D.N., and Willard D.A. J. Clin. Pharmacol. 24 (1984) 422
4. Singhvi S.M., Duchin K.L., and Morrison R.A. Br. J. Clin. Pharmacol. 25 (1988) 9
5. Dean A.V., Kripalani K.J., Everett D.W., and Migdalof B.H. Pharm. Res. 3 suppl. (1986) 152s
6. Jemal M., Ivaskiv E., Ribick M., and Cohen A.I. J. Chromatogr. 345 (1985) 299
7. Jancic B., Ivanovic D., Medenic M., Malenovic A., and Dimkovic N. J. Chromatogr. A 1088 (2005) 187
8. Tu J.I., Brennan J., Stouffer B., and Eckelman W.C. Ther. Drug Monit. 12 (1990) 401
9. Greenbaum R., Zucchelli P., Caspi A., Nouriel H., Paz R., Sclarovsky S., O'Grady P., Yee K.F., Liao W.C., and Mangold B. Br. J. Clin. Pharmacol. 49 (2000) 23
10. Jemal M., and Mulvana D.E. J. Chromatogr. B 739 (2000) 255
11. Janci B., Medenica M., Ivanovic D., Malenovic A., and Markovic S. Anal. Bioanal. Chem. 383 (2005) 687
12. Erk N. J. Pharm. Biomed. Anal. 27 (2002) 901
13. Hillaert S., De Grauwe K., and Van den Bossche W. J. Chromatogr. A 924 (2001) 439
14. Hillaert S., and Van den Bossche W. J. Pharm. Biomed. Anal. 25 (2001) 775
15. Hillaert S., and Van den Bossche W. J. Chromatogr. A 895 (2000) 33
16. US Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Guidance for Industry, Bioanalytical Method Validation, May 2001, p. 4.
17. Tuytten R., Lemière F., Witters E., Van Dongen W., Slegers H., Newton R.P., Van Onckelen H., and Esmans E.L. J. Chromatogr. A 1104 (2006) 209
18. Li W.-y., Ji J.-z., Guo J.-f., Zhang Y.-f., and Zhong D.-f. Acta Pharmaceutica Sinica 35 (2000) 601
19. Jermal M., Huang M., Mao Y., Whigan D., and Schuster A. Rapid Commun. Mass Spectrom. 14 (2000) 10
20. Hui K.K., Duchin K.L., and Kripalani K.J. J. Clin. Pharm. Ther. 49 (1991) 457